IP Group (IPO) H1 2024 earnings summary

Executive summary

• Portfolio maturity is reflected in accelerated exits, successful funding rounds, and clinical progress, with H1 2024 cash realizations surpassing prior years and a notable £30m Garrison sale.

• Maintained strong balance sheet and capital returns, including a completed £20m buyback and a further £10m announced, despite a 9% NAV per share decline mainly due to Oxford Nanopore.

• Portfolio companies raised £380m in H1 2024, with significant milestones in life sciences, deeptech, and cleantech.

• Four therapeutics companies reported positive clinical trial data in H1 2024.

• Positive momentum is expected in H2, with further exits and value creation anticipated as markets improve.

Financial highlights

• H1 2024 net loss was £109.9m, with Oxford Nanopore contributing £94.9m of the loss; NAV per share declined 9% to 104.7p.

• Gross cash at period end was £161.3m, rising to £183.7m post-Garrison exit.

• Net overheads reduced to £8.7m, a 16% year-over-year decrease, with a targeted 25% annualized reduction by year-end.

• £95m returned to shareholders since 2021, with buybacks retiring about 4% of share capital.

• Portfolio investment totaled £49.1m across 23 companies in H1 2024.

Outlook and guidance

• Anticipates further material exits at or above 2023 carrying values, with several transactions at advanced negotiation stages.

• Expects double-digit NAV per share returns in the near term, above the historical 7-8% average.

• Only 2% of larger portfolio companies need to raise funds before end of 2024; 34% funded to expected profitability.

• Hysata's first commercial units expected from 2026, with peak CapEx over the next few years.

• Continued focus on cost control and capital discipline, with future cash returns to shareholders primarily via buybacks if share price discount to NAV exceeds 20%.